康希诺生物 CanSinoBIO

Keywords you search：

1 THIRD QUARTERLY REPORT FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023

Description
2 Monthly Return of Equity Issuer on Movements in Securities

Description
3 CanSinoBIO will be included in the MSCI China All Share Small Cap Index

Description
4 VOLUNTARY ANNOUNCEMENT INITIATION OF PHASE I CLINICAL TRIAL AND COMPLETION OF FIRST PATIENT ENROLLMENT FOR RECOMBINANT ZOSTER VACCINE

Description
5 RESIGNATION OF CHIEF FINANCIAL OFFICER

Description
6 CanSinoBIO Kicks-off the Polio VLP Vaccine Cooperation

Description
7 VOLUNTARY ANNOUNCEMENT RECOMBINANT COVID-19 XBB.1.5 VARIANT VACCINE FOR INHALATION (ADENOVIRUS TYPE 5 VECTOR) INCLUDED FOR EMERGENCY USE

Description
8 Monthly Return of Equity Issuer on Movements in Securities

Description
9 VOLUNTARY ANNOUNCEMENT INITIATION OF PHASE I CLINICAL TRIAL AND COMPLETION OF FIRST PATIENT ENROLLMENT FOR TDCP ADOLESCENT AND ADULT

Description
10 CanSinoBIO and SPIMACO Forge Strategic Partnership to Advance Accessibility of Cutting-Edge Vaccines

Description

First Page Pre. Page Current Page(55) Next Page End Page(63)